Psychiatry AdvisorGLP-1 Linked to Lower Mortality and Cardiovascular Risk in Serious Mental Illness

ℹ️ Observational Association Only Evidence

People with serious mental illness experience substantially higher rates of cardiovascular disease and premature mortality than the general population. Using TriNetX electronic health record data, investigators conducted a target-trial emulation comparing initiation of GLP-1 receptor agonists with SGLT2 inhibitors in more than 1.5 million propensity-matched adults. Among the 390,368 participants with serious mental illness, GLP-1 RA initiation was associated with lower all-cause mortality and lower rates of multiple cardiovascular outcomes, raising interest in whether these agents may provide benefits extending beyond glycemic control and weight management.

Clinical Considerations

• Among patients with serious mental illness, 4-year mortality was 4.91% in GLP-1 RA users versus 6.45% in SGLT2 inhibitor users, corresponding to a relative risk of 0.76 and an absolute risk reduction of 1.54 percentage points.
• Benefits were observed across multiple cardiovascular outcomes, including reductions in 3-point MACE, 5-point MACE, myocardial infarction, stroke, heart failure, and coronary artery bypass grafting among patients with serious mental illness and type 2 diabetes.
• Exploratory subgroup analyses demonstrated lower mortality for semaglutide versus SGLT2 inhibitors among patients with major depressive disorder, bipolar disorder, and schizophrenia, suggesting the association was not confined to a single psychiatric diagnosis.
• Combination therapy with semaglutide plus an SGLT2 inhibitor was associated with lower mortality than SGLT2 inhibitor monotherapy across 1-, 4-, and exploratory 10-year analyses.
• The study employed robust propensity-score matching and a target-trial emulation design but remained observational and therefore vulnerable to residual confounding, treatment-selection bias, and differences in healthcare access.
• Limited follow-up for newer agents, particularly tirzepatide, warrants caution when interpreting class-wide conclusions.

Practice Applications

• Recognize that cardiovascular risk reduction is increasingly relevant when selecting therapies for patients with serious mental illness, who carry a disproportionate burden of cardiometabolic disease.
• Consider emerging evidence suggesting GLP-1 receptor agonists may provide benefits beyond weight loss and glycemic control, although randomized evidence specifically in psychiatric populations remains limited.
• Avoid interpreting these findings as proof that GLP-1 RAs are superior to SGLT2 inhibitors for all patients with serious mental illness, given the observational design.
• Continue individualized medication selection based on diabetes status, cardiovascular risk profile, obesity, tolerability, access, insurance coverage, and guideline recommendations.
• Monitor future prospective and randomized studies evaluating cardiometabolic interventions specifically in psychiatric populations.